Literature DB >> 15266107

Evidence for Selection of more Adapted Human Immunodeficiency Virus Type 1 Recombinant Strains in a Dually Infected Transfusion Recipient.

Luciana Jesus Costa1, Allen J Mayer, Michael P Busch, Ricardo Sobhie Diaz.   

Abstract

Human immunodeficiency virus type-1 (HIV-1) genetic diversity is one of the remarkable characteristics of these viruses, and the mechanisms involved in the selective forces driving HIV-1 evolution are of great interest. Samples from hosts infected with multiple distinct strains represent a valuable in vivo resource to investigate the role of recombination in the natural evolution of HIV-1. This work describes a detailed study regarding the evolution of the envelope gene (env) (C2-V5 region) in a dually infected child who received blood transfusions simultaneously from two distinct HIV-1 infected donors. In this study, we were able to directly compare the data obtained from the dually infected recipient with data obtained from two other singly HIV-1 infected children who had received blood transfusion from each of the two donors. Sequences from the singly infected children clustered into two distinct groups, each related to the respective donor-derived sequence by phylogenetic analysis, and hence were consistent with the epidemiological data. In the case of the dually infected child, a high degree of recombination between the two donor-derived sequences was observed at the C2-V3 region, whereas in the V4-V5 region selection of only one derived donor sequence was seen. Measurement of nonsynonymous versus synonymous substitution rates at each region revealed that negative selection was the main evolutionary force acting on the viral population of the dually infected child, regardless of the genetic mechanism by which each region evolved. Based on direct comparison with data obtained for the two singly infected children we propose that the higher amount of viral diversity observed in HIV-1 multi-infection events, as in the case of the dually infected patient, might contribute to maximizing selective advantage and possibly minimizing immune response. We conclude that recombination shaped by selective forces may increase the adaptive potential of HIV-1.

Entities:  

Mesh:

Year:  2004        PMID: 15266107     DOI: 10.1023/b:viru.0000025773.12621.a8

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  34 in total

1.  Retroviral recombination and reverse transcription.

Authors:  W S Hu; H M Temin
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

2.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

3.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group.

Authors:  R S Diaz; E C Sabino; A Mayer; J W Mosley; M P Busch
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

5.  Intra-host versus inter-host selection: viral strategies of immune function impairment.

Authors:  S Bonhoeffer; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

7.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

Authors:  F Gao; D L Robertson; C D Carruthers; S G Morrison; B Jian; Y Chen; F Barré-Sinoussi; M Girard; A Srinivasan; A G Abimiku; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Accuracy of replication in the polymerase chain reaction. Comparison between Thermotoga maritima DNA polymerase and Thermus aquaticus DNA polymerase.

Authors:  R S Diaz; E C Sabino
Journal:  Braz J Med Biol Res       Date:  1998-10       Impact factor: 2.590

Review 10.  Recombination in HIV: an important viral evolutionary strategy.

Authors:  D S Burke
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

View more
  3 in total

1.  Homogenous HIV-1 subtype B quasispecies in Brazilian men and women recently infected via heterosexual transmission.

Authors:  Nancy Lima Gouveia; Michelle Camargo; Marcos Montani Caseiro; Luiz Mario Ramos Janini; Maria Cecilia Araripe Sucupira; Ricardo Sobhie Diaz
Journal:  Virus Genes       Date:  2014-02-14       Impact factor: 2.332

2.  Nef gene evolution from a single transmitted strain in acute SIV infection.

Authors:  Benjamin N Bimber; Pauline Chugh; Elena E Giorgi; Baek Kim; Anthony L Almudevar; Stephen Dewhurst; David H O'Connor; Ha Youn Lee
Journal:  Retrovirology       Date:  2009-06-08       Impact factor: 4.602

3.  HIV-1 sequence evolution in vivo after superinfection with three viral strains.

Authors:  Karolina Kozaczynska; Marion Cornelissen; Peter Reiss; Fokla Zorgdrager; Antoinette C van der Kuyl
Journal:  Retrovirology       Date:  2007-08-23       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.